US/UK/Canada

Share

About Us

Active Biotech's activity is in the biomedical area. The company focuses on R & D.

Pick a time period -
Tags ( Active)

Interim Report January - March 2001

The Active Biotech Group Interim Report January - March 2001 · Both key projects, SAIK-MS and TTS, are proceeding to Phase II clinical trials · Increased focus on research projects in Lund · Financing through partnerships, possible sale of operations and new share issue · Operating loss of SEK -87.6 million for the period (SEK -51.5 million), adjusted pro forma year 2000 to SEK -67.8 million · Vaccine sales of SEK 46.7 million (SEK 53.4 million) Active Biotech plans to separate and further streamline its operations, investing heavily in the project portfolios while focusing on a partner

Active Biotech fulfills important milestone for the SAIK-MS project

Active Biotech fulfills important milestone for the SAIK-MS project The clinical Phase 1 study on Active Biotech's SAIK-MS compound, ABR- 215062 in healthy volunteers and MS patients is concluded. The study has successfully reached its clinical endpoint, and has provided the future clinical development programme with valuable information. A million people worldwide are affected by multiple sclerosis (MS), a chronic autoimmune disease. The body's own immune defence attacks the insulating myelin sheaths surrounding the nerve fibres in the central nervous system, thereby disrupting or

Annual General Meeting of Shareholders in Active Biotech 29 March 2001

Annual General Meeting of Shareholders in Active Biotech 29 March 2001 At Active Biotech AB´s Annual General Meeting Sven Andréasson, Mats Arnhög, Maria Borelius, Svend Holst-Nielsen, Mats Pettersson, Peter Sjöstrand and Hugo Thelin were re-elected. Hugo Thelin will continue serving as Chairman of the Board. Anders Williamsson and Håkan Åström, who have renounced a re-election due to other commitments, were thanked for their services by the Chairman of the Board, HugoThelin. The President & CEO, Sven Andréasson´s speech at the General Meeting is available for download (as well as the Annual

Active Biotech in collaboration with Aventis Pasteur MSD regarding distribution and marketing of vaccines in Sweden

Active Biotech in collaboration with Aventis Pasteur MSD regarding distribution and marketing of vaccines in Sweden Active Biotech AB, through its subsidiary SBL Vaccin AB, and Aventis Pasteur MSD announce that they will initiate a collaboration regarding marketing and distribution of vaccines, and will now start a close collaboration on the Swedish market. Aventis Pasteur MSD is a leading vaccine company in Europe, exclusively specialised in vaccines. SBL Vaccin Distribution is the market leader in Sweden, with the distribution of vaccines to 8 000 customers, including county councils and

Invitation to Annual General Meeting of Shareholders

Invitation to Annual General Meeting of Shareholders The Board of Directors of Active Biotech AB (publ) has today issued a notification of the Annual General Meeting, which is to take place at 17.00 on 29 March 2001 at the Scandic Star Hotel, Glimmervägen 5, in Lund. The notification is published in today's editions of Sydsvenskan, Svenska Dagbladet and Post- och Inrikes Tidningar. ACTIVE BIOTECH AB (PUBL) THE BOARD OF DIRECTORS Active Biotech AB is a biotechnics company focusing on research and development of medicines and vaccines. Our expertise lies in the knowledge of the human immune

The Active Biotech Group Final Accounts Report For The 2000 Operating Year

The Active Biotech Group Final Accounts Report For The 2000 Operating Year · SAIK-MS phase I study now also includes MS patients · TTS phase I study completed · GAS-vaccine - high protective effect · Increase in vaccine sales by 26% · Profit/loss after net financial items (before items affecting comparability) MSEK -148.6 -according to forecast (MSEK -150) · Profit/loss after items affecting comparability MSEK -419.3 million (MSEK -62.0) Clinical studies now include MS patients A million people worldwide are affected by multiple sclerosis, a chronic autoimmune disease. The body's own immune

Half-Year Accounts January - June 2000

Half-Year Accounts January - June 2000 * Results according to schedule, MSEK -59 (-75 previous year) * Vaccine sales increase by 20% * Continued positive development for Dukoral +42% * Aventis Pasteur new business partner * SAIK and TTS according to plan * Major new order for SBL Cholera Vaccine worth MSEK 7.4 * New technology platforms established * Increase in turnover 18%, results MSEK -59 (-75) Sales of vaccines amounted to MSEK 102.7 (85.5), an increase of 20% compared with the corresponding period last year. Continued positive development for Dukoral in Sweden and Norway, 42% sales

Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against traveller€s diarrhoea

Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against traveller's diarrhoea Active Biotech has taken back the worldwide rights for the ETEC vaccine project. The ongoing phase III clinical trials in Mexico and Guatemala are continuing according to plan. Alternative partnering strategies are under evaluation as well as the future clinical trials program. Furthermore, all the international marketing rights for the SBL Cholera Vaccine have been transferred back to Active Biotech. As part of the agreement, SmithKline Beecham's (SB) paediatric vaccines,

Active Biotech concludes agreement with Aventis Pasteur

Active Biotech concludes agreement with Aventis Pasteur Active Biotech has started collaboration with Aventis Pasteur within the field of diarrhoea diseases. Aventis Pasteur will assume responsibility for the marketing, sales and distribution of Active Biotech's drinkable cholera vaccine, SBL Cholera Vaccine for all countries worldwide outside USA and Europe. The product has received a recommendation from the World Health Organisation (WHO), as the only vaccine on the market with a documented effect against cholera. Cholera is an acute intestinal infection with dramatic effects, occurring

Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB

Active Biotech AB accepts offer from Carl Bennet AB on shares in Lifco AB The Board of Active Biotech AB has decided to accept Carl Bennet AB's public offer on shares in Lifco AB at the price of 42 SEK per share. The shares will be transfered in accordance with the offer. Active Biotech's shareholding amounts to 1 812 103 Lifco serie B, corresponding to 19,9% of the capital and 12,5% of the votes. The stockholding is a financial asset and a capital gain of 11,0 MSEK will arise upon sale. Lund 2 August 2000 Active Biotech AB (publ) Sven Andréasson President & CEO Active Biotech AB is a

Active Biotech shareholders meeting 12 april 2000

(for OH-pictures from the President & CEO's speech, see www.activebiotech.com) ACTIVE BIOTECH SHAREHOLDERS' MEETING 12 APRIL 2000 * The ETEC project continues with full force * Vaccine sales during the first quarter of the year: turnover increased by 48 % compared to the previous year * The sales of Dukoral and SBL Cholera Vaccine increased by 255% * Preliminary results after financial posting: +20 million SEK. * MGA Holding: a new big shareholder in Active Biotech AB Sven Andréasson's (President & CEO) speech at the shareholders' meeting The ETEC project Two weeks ago we announced new

Preliminary results from the first Phase lll-study of the ETEC-vaccine

Preliminary results from the first Phase lll-study of the ETEC-vaccine There are two phase III studies for the candidate ETEC vaccine against travellers diarrhoea both coordinated by Johns Hopkins School of Hygiene and Public Health in Baltimore, USA. These are in Guatemala and in Mexico. The first study, with Professor David Sack as principal investigator, comprising 671 travellers has recently been completed. Data analyses show that the primary clinical endpoint as defined was not met i.e. protection against travellers' diarrhoea caused by vaccine preventable ETEC infection. However,

Invitation to Annual Meeting of Shareholders

Invitation to Annual Meeting of Shareholders The Board of Directors of Active Biotech AB (publ) has today issued a notification of the Annual General Meeting, which is to take place at 17.00 on 12 April 2000 at the Star Hotel in Lund. The notification is published in today´s editions of Sydsvenskan, Svenska Dagbladet and Post- och Inrikes tidningar. ACTIVE BIOTECH AB (PUBL) THE BOARD OF DIRECTORS Active Biotech AB is a Swedish biotechnology company focused on the research and development of pharmaceuticals and vaccines; our core competence being our knowledge of the human immune system. We

Patent for SAIK-MS approved in the USA

Patent for SAIK-MS approved in the USA Active Biotech has received patent approval for a group of chemical substances containing candidate drugs against autoimmune and inflammatory diseases. The application in the USA was presented in April 1999 and the product and use patent has now been approved with a patent life of 20 years, valid until 2019. International patent applications were also applied for during 1999 and are pending. One of these substances is being investigated in an ongoing extended phase I clinical trial which also includes patients with the disease multiple sclerosis, MS.

Annual Accounts Report January - December 1999

Annual Accounts Report January - December 1999 * Active Biotech invests in new pharmaceuticals against cancer * Sale of Polio vaccine to new partner * SAIK goes into Phase I clinical trials in MS patients * ETEC-vaccine - first data on efficacy by the end of the quarter * Dukoral travel vaccine, 70 % increase in sales in 1999, 100 % increase in January this year * New international order for SBL Cholera Vaccine * Results better than prognosis, -58 million SEK net * Available assets 680 million SEK. Real estate payment in April gives another 122 million SEK ACTIVE BIOTECH INVESTS IN NEW

The Swedish Medical Products Agency has approved for Active Biotech to expand Phase I-trials and include patients with m

The Swedish Medical Products Agency has approved for Active Biotech to expand Phase I-trials and include patients with multiple sclerosis During the autumn 1999, SAIK-MS, a substance intended for use in patients with multiple sclerosis, has been tested on healthy volunteers with very promising results. The Swedish medical products agency has now approved a more extensive study in more subjects with higher doses. A later phase will also be included in this extended Phase I-trial, in which tolerance and dosing studies will be carried out in diseased patients. It is therefore anticipated that

New production manager for Active Biotech

Börje Haag has been appointed production manager at Active Biotech AB and will be taking up his position in February being based at SBL Vaccin in Solna, Sweden. He is presently Vice President, Production at Pharmacia & Upjohn's Strängnäs factory, employing the use of biotechnology in pharmaceutical production and has held production positions at a number of other companies, including ASTRA. The appointment of Börje Haag secures for Active Biotech the competence required to meet our current and future international production requirements. Recently, in October, an investment of SEK 30

Active Biotech sells its premises in Solna for SEK 190 million

PRESS RELEASE *Active Biotech sells its premises in Solna for SEK 190 million with possible incremental payments *A capital gain of SEK 110 million for 1999, corresponding to SEK 10 per share *Research centralised in Sweden *Result for 1999 estimated to be SEK 50 million better than previous forecast Active Biotech has concluded an agreement to sell their premises and property in Solna to the Norwegian real estate company Selmer for SEK 190 million, plus further possible incremental payments. The property sale is part of Active Biotech's strategy to free capital to enable it to concentrate

Interim Report 1 January - 30 September 1999

Interim Report 1 January - 30 September 1999 * The new annual forecast shows a considerably better result. Sale of the property in Solna expected to be completed before the end of the year * New organisation - annual savings totalling SEK 75m * ETEC vaccine - Phase III clinical trials in final stage. Efficacy data published during Q1, 2000 * Great export potential for Dukoral travel vaccine. Record sales in Sweden, +70% * SAIK-MS in extended Phase I - great interest from partners * Extended research partnership with OXiGENE * Available liquid funds: SEK 648m, equivalent to SEK 58 per share *

Altered day regarding financial information for Active Biotech

Altered day regarding financial information for Active Biotech Interim report, nine months, will be published on Monday, 22 November 1999, and not, as previously indicated, on 25 November. Final accounts report for 1999 will be published on 18 February 2000. Lund 12 November 1999 Active Biotech AB (publ) Sven Andréasson President & CEO Active Biotech AB is a Swedish biotechnology group focused on the research and development of pharmaceuticals and vaccines. Our core competence is knowledge of the human immune defence system. We have a high qualitative project portfolio and considerable

Increased institutional ownership in Active Biotech

Increased institutional ownership in Active Biotech Bo Håkansson with company has sold 300.000 B-shares in Active Biotech AB (publ). The shares are sold to Swedish institutional investors. After the sale Bo Håkansson's shareholding amounts to 1.289.519 A-shares representing 11,5% of the capital and 44,5% of the votes. Furthermore Bo Håkansson holds 81.500 share options. Malmö 24 September 1999 Bo Håkansson Executive Chairman, Active Biotech AB ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available

Half Year Report January - June 1999

Active Biotech Group Half Year Report January - June 1999 * SmithKline Beecham gives top priority to the ETEC-vaccine * completes Phase III trials in a new project organisation * Investing in increased production capacity for the ETEC-vaccine * The cholera vaccine - international breakthrough following WHO recommendation * SAIK-MS in Phase I - great market potential * Focusing and integration provide savings of approx. 75 MSEK a year * Pre-tax profit -74.9 MSEK, 20 MSEK better than plan * Shareholders' equity per share 93 SEK and available liquid funds per share 64 SEK * Group equity/assets

There are no items matching the current filter
There are no more items matching the current filter
Back to top